Table 1.
List of autologous cellular immunotherapies using the CRISPR-Cas9-based gene editing system.
| Conditions Targeted |
Targets Knocked out via CRISPR | Targets Knocked in (via Lentivirus or CRISPR) | Sponsor | Clinical Trial ID |
|---|---|---|---|---|
| Advanced hepatocellular carcinoma | PD1 | Central South University | NCT04417764 [43] | |
| Advanced esophageal squamous cell carcinoma | PD1 | Hangzhou Cancer Hospital | NCT03081715 [44] | |
| Metastatic gastrointestinal cancers |
CISH | Intima Bioscience, Inc. | NCT04426669 [60] | |
| Metastatic non-small cell lung cancer | NCT05566223 [59] | |||
| Metastatic non-small cell lung cancer | PD1 | Sichuan University | NCT02793856 [45] | |
| EBV+ malignancies | PD1 | Nanjing University | NCT03044743 [46] | |
| CD5+ relapsed/refractory T cell malignancies | CD5 | CD5-CAR (via lentivirus) |
Huazhong University | NCT04767308 [61] |
| Acute lymphocytic leukemia | HPK-1 | CD19-CAR (via lentivirus) |
Xijing Hospital | NCT04037566 [62] |
| Multiple solid tumors | PD1 and TRAC | Mesothelin-CAR (via lentivirus) |
Chinese PLA General Hospital | NCT03545815 [47] |
| Mesothelin-positive multiple solid tumors |
NCT03747965 [48] | |||
| Advanced EGFR-positive solid tumors | TGF-β receptor Ⅱ | EGFR-CAR (via lentivirus) |
NCT04976218 [63] | |
| Multiple myeloma | PD1, TRAC and TRBC | NY-ESO-1-TCR (via lentivirus) |
University of Pennsylvania | NCT03399448 [49] |
| Acute myeloid leukemia | TRBC and TRAC | Wilms Tumor 1-TCR (via CRISPR) |
Intellia Therapeutics | NCT05066165 [64] |